|
Collaborations (Details)
|
3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 11 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 11 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
USD ($)
|
Sep. 30, 2013
USD ($)
|
Jun. 30, 2013
USD ($)
|
Mar. 31, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Sep. 30, 2012
USD ($)
|
Jun. 30, 2012
USD ($)
|
Mar. 31, 2012
USD ($)
|
Dec. 31, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2013
Erbitux [Member]
USD ($)
|
Dec. 31, 2012
Erbitux [Member]
USD ($)
|
Dec. 31, 2011
Erbitux [Member]
USD ($)
|
Dec. 31, 2013
Effient [Member]
USD ($)
|
Dec. 31, 2012
Effient [Member]
USD ($)
|
Dec. 31, 2011
Effient [Member]
USD ($)
|
Aug. 31, 2012
Amylin [Member]
USD ($)
|
Nov. 30, 2011
Amylin [Member]
USD ($)
|
Dec. 31, 2012
Amylin [Member]
USD ($)
|
Dec. 31, 2011
Amylin [Member]
USD ($)
|
Dec. 31, 2013
Exenatide [Member]
USD ($)
|
Dec. 31, 2012
Exenatide [Member]
USD ($)
|
Dec. 31, 2011
Exenatide [Member]
USD ($)
|
Mar. 31, 2011
Boerhringer Ingelheim (BI) [Member]
USD ($)
|
Dec. 31, 2013
Boerhringer Ingelheim (BI) [Member]
USD ($)
|
Dec. 31, 2012
Boerhringer Ingelheim (BI) [Member]
USD ($)
|
Dec. 31, 2011
Boerhringer Ingelheim (BI) [Member]
USD ($)
|
Oct. 31, 2013
Tanezumab [Member]
USD ($)
|
Dec. 31, 2013
United States [Member]
USD ($)
|
Dec. 31, 2012
United States [Member]
USD ($)
|
Dec. 31, 2011
United States [Member]
USD ($)
|
Nov. 30, 2011
Secured Note [Member]
Amylin [Member]
|
Jun. 30, 2011
Loan Commitment [Member]
Exenatide Once Weekly [Member]
USD ($)
|
Nov. 30, 2011
Sales New [Member]
Amylin [Member]
USD ($)
|
Nov. 30, 2011
Sales New [Member]
Outside the United States [Member]
Exenatide [Member]
|
Aug. 31, 2012
Revenue Share [Member]
Amylin [Member]
USD ($)
|
Nov. 30, 2011
Revenue Share [Member]
United States [Member]
Amylin [Member]
|
Nov. 30, 2011
Revenue Share [Member]
Outside the United States [Member]
Amylin [Member]
|
Nov. 30, 2011
Milestone Payments [Member]
Amylin [Member]
USD ($)
|
Dec. 31, 2008
Milestone Payments [Member]
Solanezumab [Member]
USD ($)
|
Dec. 31, 2013
Milestone Payments [Member]
BI compounds [Member]
USD ($)
|
Dec. 31, 2013
Milestone Payments [Member]
BI compounds [Member]
EUR (€)
|
Dec. 31, 2011
Milestone Payments [Member]
BI compounds [Member]
USD ($)
|
Dec. 31, 2013
Milestone Payments [Member]
LLY compounds [Member]
USD ($)
|
Mar. 31, 2011
Milestone Payments [Member]
LLY optional compound [Member]
USD ($)
|
Dec. 31, 2009
Milestone Payments, Sales-based [Member]
Baricitinib [Member]
USD ($)
|
Oct. 31, 2013
Milestone Payments, Sales-based [Member]
Tanezumab [Member]
USD ($)
|
Dec. 31, 2013
Milestone Payments, Development and Regulatory [Member]
LLY compounds [Member]
USD ($)
|
Dec. 31, 2012
Milestone Payments, Development and Regulatory [Member]
Baricitinib [Member]
USD ($)
|
Dec. 31, 2013
Milestone Payments, Development and Regulatory [Member]
Baricitinib [Member]
USD ($)
|
Oct. 31, 2013
Milestone Payments, Development and Regulatory [Member]
Tanezumab [Member]
USD ($)
|
Dec. 31, 2013
Profit And Development And Marketing Share [Member]
Effient [Member]
|
Dec. 31, 2009
Royalty [Member]
Baricitinib [Member]
|
Dec. 31, 2009
Research And Development Exp [Member]
Baricitinib [Member]
|
Nov. 30, 2011
Research And Development And Marketing And Selling Expense [Member]
United States [Member]
Exenatide [Member]
|
Nov. 30, 2011
Gross Margin Share [Member]
United States [Member]
Exenatide [Member]
|
Dec. 31, 2008
Royalty Payments Received [Member]
Solanezumab [Member]
|
|
| Sales Revenue, Goods, Net | $ 58,500,000 | $ 76,400,000 | $ 87,600,000 | $ 508,700,000 | $ 457,200,000 | $ 302,500,000 | $ 133,100,000 | $ 207,800,000 | $ 179,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Collaboration and other revenue | 707,500,000 | 633,000,000 | 681,700,000 | 315,200,000 | 320,600,000 | 321,600,000 | 0 | 70,100,000 | 243,100,000 | 249,200,000 | 88,600,000 | 15,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| Total Revenue | 5,808,800,000 | 5,772,600,000 | 5,929,700,000 | 5,602,000,000 | 5,957,300,000 | 5,443,300,000 | 5,600,700,000 | 5,602,000,000 | 23,113,100,000 | 22,603,400,000 | 24,286,500,000 | 373,700,000 | 397,000,000 | 409,200,000 | 133,100,000 | 277,900,000 | 422,700,000 | 12,889,700,000 | 12,313,100,000 | 12,977,200,000 | ||||||||||||||||||||||||||||||||||||||
| Other Nonoperating Income (Expense) | 63,900,000 | (41,000,000) | (72,900,000) | 787,800,000 | 0 | 495,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research and Development Expense | 5,531,300,000 | 5,278,100,000 | 5,020,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds from prepayment of revenue-sharing obligation | 0 | 1,212,100,000 | 0 | 1,210,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Collaborative Arrangement, Income Statement Classification and Amounts | 203,700,000 | 188,500,000 | 125,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Collaborative Arrangement, Rights and Obligations | (250,000,000) | (1,260,000,000) | (150,000,000) | (70,000,000) | (225,000,000) | (478,700,000) | 250,000,000 | 525,000,000 | (150,000,000) | 50,000,000 | (50,000,000) | (415,000,000) | ||||||||||||||||||||||||||||||||||||||||||||||
| Collaborative Arrangement, Rights and Obligations, Terms | 97,200,000 | 1,230,000,000 | 350,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Collaborative Arrangement, Rights and Obligations Percent | 15.00% | 100.00% | 65.00% | 35.00% | 50.00% | 20.00% | 30.00% | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds from Sales of Business, Affiliate and Productive Assets | 1,200,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt Instrument, Interest Rate, Stated Percentage | 9.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Collaborative Arrangement, Rights and Obligations, Term of Arrangement | 10 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Acquired in-process research and development | 57,100,000 | 0 | 0 | 0 | 57,100,000 | 0 | 388,000,000 | 388,000,000 | 200,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Payments to Fund Long-term Loans to Related Parties | $ 165,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||